Description:
New Page 1
CEFA-DROPS® / CEFA-TABS®
Rx
Fort Dodge
CEFADROXIL
Veterinary Powder for Oral Suspension
Veterinary Tablets
Veterinary Film-Coated Tablets
NADA 140-684 and 119-688, Approved by FDA
CEFA-DROPS (cefadroxil) and CEFA-TABS (cefadroxil)
contain a semi-synthetic cephalosporin antibiotic intended for oral
administration. CEFA-DROPS has an orange-pineapple flavor.
CLINICAL PHARMACOLOGY
Action
Cefadroxil, like other beta-lactam antibiotics,
is a bactericidal agent that causes death of bacterial cells through a diversity
of biological and biochemical effects on the cell wall. The spectrum of
antibacterial activity includes many gram-negative organisms since cefadroxil,
like other cephalosporins, has the ability to penetrate the outer envelope of
gram-negative bacilli, thereby gaining access to cell wall target sites.
Cefadroxil is generally not broken down by penicillinases such as those produced
by penicillin-resistant staphylococci, although cephalosporinases have been
identified that can inactivate the molecule.
Microbiology
The effectiveness of CEFA-DROPS and CEFA-TABS
in skin and soft tissue infections caused by Staphylococcus aureus,
(including penicillin-resistant strains) and in urinary tract infections caused
by Staphylococcus aureus, Escherichia coli and Proteus mirabilis,
has been demonstrated clinically in the dog. In cats, the effectiveness of
cefadroxil in skin and soft tissue infections caused by susceptible pathogens
such as Pasteurella multocida, Staphylococcus aureus, Staphylococcus
epidermidis and Streptococcus spp. has also been demonstrated. In
addition, cefadroxil has a broad spectrum of activity against both gram-positive
and gram-negative human isolates. Although the clinical significance of in
vitro data is unknown in the target species, the following human isolates
are generally susceptible to cefadroxil at the indicated concentrations1.
|
Organism
|
No. of Isolates |
Minimum Inhibitory Concentration
(mcg/mL) |
|
Range |
MIC90* |
|
Streptococcus pyogenes |
(24) |
0.063-0.125 |
0.11 |
|
Streptococcus agalactiae |
(27) |
0.25-1 |
0.92 |
|
Streptococcus pneumoniae |
(29) |
0.5-2 |
1.2 |
|
Staphylococcus aureus,
penicillin sensitive |
(16) |
2-16 |
3.2 |
|
Staphylococcus aureus,
penicillin resistant |
(63) |
1-32 |
6.2 |
|
Staphylococcus epidermidis |
(28) |
0.125-4 |
2.13 |
|
Escherichia coli |
(59) |
4->125 |
16.0 |
|
Proteus mirabilis |
(62) |
4->125 |
15.6 |
|
Klebsiella pneumoniae |
(61) |
4-16 |
7.85 |
|
Salmonella
spp. |
(22) |
4-8 |
7.19 |
|
Shigella spp. |
(12) |
2-8 |
6.98 |
|
Pasteurella multocida |
(2) |
|
1.4 |
*Concentration at which 90% of the isolates are
susceptible.
The susceptibility of organisms to cefadroxil
should be determined using the cephalosporin class disc, 30 mcg. Specimens for
susceptibility testing should be collected prior to the initiation of antibiotic
therapy.
Pharmacokinetics
Cefadroxil is stable in gastric acid and only
moderately bound to serum proteins (approximately 20%). Cefadroxil is well
absorbed from the gastrointestinal tract even when administered with food. The
drug is excreted largely unchanged by the kidney. In humans, high concentrations
of cefadroxil activity are found in urine within three hours after oral dosage2.
The concurrent administration of probenecid retards the elimination rate.
In dogs, oral administration of cefadroxil at a
dosage of 10 mg/lb results in mean peak serum concentrations averaging 18.6 mcg/mL
within 1 to 2 hours after treatment3. The serum half-life (T½)
following oral administration is approximately 2 hours. Over 50% of an orally
administered dose is excreted unchanged in the urine of dogs within 24 hours.
Serum concentration time profiles in dogs following oral administration are
illustrated graphically in Figure 1.
Figure 1: Cefadroxil Serum Concentration Curves
in Dogs3
In cats, oral administration of cefadroxil at a
dosage of 10 mg/lb results in mean peak serum concentrations of 17.4 mcg/mL
within 1 to 2 hours after treatment. The serum half-life (T½) following oral
administration to cats is 2½ to 3 hours. Serum concentration time profiles in
cats following oral administration are illustrated graphically in Figure 2.
Figure 2: Cefadroxil Serum Concentration Curves
in Cats
INDICATIONS
CEFA-DROPS (cefadroxil) and CEFA-TABS (cefadroxil)
are indicated for the treatment of the following conditions:
Dogs: Genitourinary
tract infections (cystitis) caused by susceptible strains of Escherichia
coli, Proteus mirabilis and Staphylococcus aureus.
Skin and soft tissue infections including
cellulitis, pyoderma, dermatitis, wound infections and abscesses caused by
susceptible strains of Staphylococcus aureus.
Cats: Skin and soft
tissue infections including abscesses, wound infections, cellulitis and
dermatitis caused by susceptible strains of Pasteurella multocida,
Staphylococcus aureus, Staphylococcus epidermidis and Streptococcus
spp.
CONTRAINDICATIONS
CEFA-DROPS and CEFA-TABS should not be
administered to dogs or cats with a known allergy to cephalosporins. In
penicillin-allergic animals, CEFA-DROPS and CEFA-TABS should be used with
caution.
WARNINGS
For use in dogs and cats only. Not to be used
in animals which are raised for food production. Safety for use in pregnant
female dogs and cats or in breeding males has not been determined (see ANIMAL
TOXICOLOGY).
ANIMAL TOXICOLOGY
In subacute studies, dogs administered 100, 200
or 400 mg/kg/day for 13 weeks showed no consistent or distinct treatment-related
histopathologic changes. In chronic toxicity studies, dogs receiving doses as
high as 600 mg/kg/day for six months showed no discernible treatment-related
effects, with the exception of emesis in dogs receiving a 400 mg/kg/day dose at
one time. No distinct or consistent meaningful drug-related changes in the
hematologic, coagulation or urinalysis test results or in histologic examination
of tissues were observed when compared to controls.
No teratogenic or antifertility effects were
seen in reproductive studies done in mice and rats receiving dosages as high as
nine times the maximum recommended canine dosage.
In cats, oral administration of cefadroxil at a
dosage of 240 mg/kg/day divided into two equal doses (ten times the recommended
daily dosage) for 21 consecutive days produced no clinical chemistry,
pathological or other signs of toxicity other than reduced food consumption,
vomiting and diarrhea.
ADVERSE REACTIONS
Occasional nausea and vomiting have been
reported following cefadroxil therapy. Administration with food appears to
decrease nausea. Diarrhea and lethargy have been occasionally reported.
DOSAGE
Dogs: CEFA-DROPS and
CEFA-TABS 1 gram, 50 mg, 100 mg and 200 mg should be administered orally at a
dosage of 10 mg/lb of body weight twice daily. Dogs with skin or soft tissue
infections should be treated for a minimum of three days. Genitourinary tract
infections should be treated for a minimum of seven days with cefadroxil.
Maximum duration of therapy should not exceed 30 days.
Cats: CEFA-DROPS and
CEFA-TABS 50 mg and 100 mg should be administered orally at a dosage of 10 mg/lb
of body weight once daily. Maximum duration of therapy should not exceed 21
days.
In both species, drug treatment should continue
for at least 48 hours after the animal is afebrile or asymptomatic. If no
response is observed after three days of treatment, therapy should be
discontinued and the case should be re-evaluated.
TO PREPARE SUSPENSION
Tap bottle lightly to loosen powder. For 15 mL
bottle, add 10.4 mL of water in two portions. For 50 mL bottle, add 34 mL of
water in two portions. Shake well after each addition. After mixing, store in
refrigerator. Shake well before use. Discard unused portion after 14 days.
Droppers supplied with CEFA-DROPS are
calibrated in mL increments. When mixed as directed, each mL contains cefadroxil
monohydrate equivalent to 50 mg cefadroxil.
CAUTION
Federal law restricts this drug to use by or on
the order of a licensed veterinarian. The enclosed dose dropper in Cefa Drops
contains natural rubber latex which may cause allergic reactions.
Store at controlled room temperature 15° to
30°C (59° to 86°F).
|